Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Next Previous
X
Search
Trial Profile

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enfortumab vedotin (Primary)
  • Indications Bladder cancer; Carcinoma; Fallopian tube cancer; Kidney-neoplasms; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Agensys; Astellas Pharma; Astellas Pharma Global Development

    • Most Recent Events

    • 06 Jan 2023 Status changed from active, no longer recruiting to completed.
    • 16 Jun 2022 Planned End Date changed from 30 Jun 2022 to 31 Dec 2022.
    • 16 Jun 2022 Planned primary completion date changed from 30 Jun 2022 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top